| GDP与CHOP方案治疗非特异性外周T细胞淋巴瘤的疗效分析 |
| |
| 引用本文： | 张明智,邢朋涛,李玲. GDP与CHOP方案治疗非特异性外周T细胞淋巴瘤的疗效分析[J]. 中国肿瘤临床, 2012, 39(12): 857-860. DOI: 10.3969/j.issn.1000-8179.2012.12.011 |
| |
| 作者姓名： | 张明智 邢朋涛 李玲 |
| |
| 作者单位： | 郑州大学第一附属医院肿瘤内科（郑州市450052） |
| |
| 摘 要： | ![]()
目的 探讨GDP方案和CHOP方案治疗非特异性外周T细胞淋巴瘤（PTCL-U）的疗效和安全性。 方法 回顾性分析自2008年1月至2011年12月郑州大学第一附属医院淋巴瘤诊疗中心收治经病理学确诊的PTCL-U患者29例。14例患者应用GDP方案，15例应用CHOP方案。采用χ2检验和Log-Rank检验，对两组的疗效及不良反应进行分析和比较。 结果 接受GDP方案化疗的非特异性外周T细胞淋巴瘤患者总有效率（RR）为78.57%，而CHOP组为60.00%，两组比较差异有统计学意义（P < 0.05）。GDP组无进展生存期（PFS）为9.79个月，总生存期（OS）为17.36个月；CHOP组PFS为4.2个月，OS为11.27个月，两组比较差异均有统计学意义（P < 0.05）。主要不良反应为血液学毒性，其中GDP方案Ⅲ~Ⅳ度血液学毒性发生率57.14%，CHOP方案Ⅲ~Ⅳ度血液学毒性为33.33%。 结论 GDP方案治疗外周T细胞淋巴瘤疗效优于传统CHOP方案，虽然血液学毒性稍重，仍值得临床推广，并有望成为PTCL治疗的一线方案。
|
| 关 键 词： | 非特异性外周T细胞淋巴瘤 GDP方案 疗效 安全性 |
| 收稿时间： | 2012-01-20 |
GDP and CHOP Chemotherapy for Nonspecific Peripheral T-cell Lymphoma |
| |
| Mingzhi ZHANG , Pengtao XING , Ling LI. GDP and CHOP Chemotherapy for Nonspecific Peripheral T-cell Lymphoma[J]. Chinese Journal of Clinical Oncology, 2012, 39(12): 857-860. DOI: 10.3969/j.issn.1000-8179.2012.12.011 |
| |
| Authors: | Mingzhi ZHANG Pengtao XING Ling LI |
| |
| Affiliation: | Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China |
| |
| Abstract: | ![]()
Objective This study aims to investigate the efficacy and safety of GDP chemotherapy for nonspecific peripheral T-cell lymphoma (PTCL) compared with the CHOP regimen. Methods Between January 2008 and December 2011, 14 nonspecific PTCL patients were treated with the GDP regimen and 15 were treated with the CHOP regimen. The curative effects and the adverse reactions were analyzed and compared between the two groups by χ2 text and Log-Rank test. Results The overall response (OR) rate was 78.57 % among the patients in the GDP group and 60 % in Objectives: the CHOP group. Statistically significant differences were observed between the two groups (P < 0. 05). The progression-free survival (PFS) rate was 9.79 months in the GDP group and 4.2 months in the CHOP group. The overall survival (OS) was 17.36 months in the GDP group and 17.27 months in the CHOP group. Statistically significant differences were observed between the two groups (P < 0. 05). The main side effect was bone marrow depression, and grade 3 or grade 4 hematologic toxicity occurred in 18.42% of the patients in the GDP group and 33.33 % of those in the CHOP group. Conclusion GDP regimen is more effective for nonspecific peripheral T-cell lymphoma than the CHOP regimens. Although the hematological toxicity of GDP regimen is serious, the regimen is expected to be the first-line treatment for PTCL. |
| |
| Keywords: | |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
